/stocks — the workspaceLOADING
All ELTP SEC filings, by type → · Earnings date & implied move · Search inside filings
ELITE PHARMACEUTICALS INC /NV/ (ELTP) is a pharmaceutical preparations company. Piotroski F-Score 7/8. 1 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-13 from ELTP's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind ELTP’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
FY ending 2026-03-31 vs 2025-03-31.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from ELTP’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on ELTP plus an auto-SWOT — built from ELTP's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ELTP using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has ELTP been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in ELTP under the STOCK Act.
No tracked institution reported a position in ELTP in the latest 13F round.
Every figure is from ELTP’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
| Dash Barry HDirector | BUY | $9K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Northvale, New Jersey, United States · the company’s charter and its head office are in different states.
EDGAR’s company directory says New Jersey, United States. We show the company’s own most recent filing. The directory is a separate record, and the two can differ in either direction: a directory entry can change before the next filing shows a reincorporation, or go on showing a jurisdiction the company has left.
Source: the cover page of ELITE PHARMACEUTICALS INC /NV/’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-10-17. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Projected from ELTP's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentELTP files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.